Article

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99

2020-02-03

Abstract excerpt

<title>Abstract</title> <p>Background The HER2 extracellular domain shed in blood (HER2 ECD ) is reported to rise and fall in parallel with HER2+ breast cancer behavior. In this study, we evaluated the clinical relevance of plasma HER2 ECD values in patients with metastatic breast cancer treated in the SAKK22/99 trial comparing trastuzumab monotherapy followed by trastuzumab-chemotherapy combination at progressio...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 09244c6b-0b9f-5b23-91a6-5196da80a158
DOI: 10.21203/rs.2.11084/v5

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: Results of a randomized study - SAKK 22/99DOI 10.21203/rs.2.11084/v5Read

Longitudinal HER2 amplification tracked in circulating tumor DNA for therapeutic effect monitoring and prognostic evaluation in patients with breast cancerSemantic proximity Read

HER2 expression identifies dynamic functional states within circulating breast cancer cells.Semantic proximity Read

Low and Ultra-low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic SubtypesSemantic proximity Read

The human epidermal growth factor receptor 2 (HER2)Semantic proximity Read

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.Semantic proximity Read

The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.Semantic proximity Read

Phase II Exploratory Study of Neoadjuvant Disitamab Vedotin and Penpulimab in HER2-low Stage II-III Breast Cancer (NeoPanDa04)Semantic proximity Read

Real-world data of eribulin in advanced and pretreated HER2-negative breast cancer in a Spanish comprehensive cancer centerSemantic proximity Read

Biomarker analyses in CLEOPATRA: a phase III, placebo-controlled study of pertuzumab in human epidermal growth factor receptor 2-positive, first-line metastatic breast cancer.Semantic proximity Read

Potential Use of Extracellular Vesicles for the HER2 Status Assessment in Breast Cancer PatientsSemantic proximity Read

Identification of markers to predict benefit from trastuzumab treatmentSemantic proximity Read

Mechanism of action and resistance to Trastuzumab Deruxtecan in patients with metastatic breast cancer: the DAISY trialSemantic proximity Read